MacroGenics (MGNX) AI Stock Analysis

• Market Cap: $94.89M
• Dividend Yield: N/A
• Average Volume (3M): 855.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.29
• Revenue Growth: -9.70%
• EPS Growth: 23.23%
• Country: US
• Employees: 341
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.27
• Shares Outstanding: 63,258,533
• 10 Day Avg. Volume: 927,519
• 30 Day Avg. Volume: 855,388
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.75
• Price to Sales (P/S): 1.37
• P/FCF Ratio: -2.82
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 0.53
• Enterprise Value/Gross Profit: 0.72
• Enterprise Value/Ebitda: -1.06
• 1Y Price Target: $3.00
• Price Target Upside: 94.81% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -1.87
• Revenue Forecast (FY): $93.22M

• Rating: 45 Neutral
• Price Target: $1.50 ▼(-2.60% Downside)

MacroGenics' overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing profitability issues and cash flow management difficulties. The technical analysis indicates a bearish trend, and the valuation metrics highlight significant concerns with a negative P/E ratio. These factors collectively contribute to a lower stock score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates expanding market reach and potential for increased market share, supporting long-term business sustainability.

Gross Profit Margin

A high gross profit margin suggests efficient production processes and strong pricing power, which can enhance long-term profitability.

Cash Generation Ability

Positive cash generation relative to net losses indicates the company can sustain operations and invest in growth despite profitability challenges.

Negative Factors

Profitability Issues

Ongoing profitability issues, as indicated by a negative net profit margin, pose a risk to financial stability and long-term viability.

Negative Return on Equity

A negative return on equity highlights inefficiencies in generating returns on shareholder investments, impacting investor confidence and financial health.

Operational Challenges

Negative operational margins suggest inefficiencies in core operations, which may hinder the company's ability to achieve sustainable profitability.

MacroGenics Business Overview & Revenue Model

Company Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

How the Company Makes Money

MacroGenics generates revenue through a combination of product sales, licensing agreements, and collaborations with pharmaceutical companies. The company earns revenue from the sale of its approved therapeutics, as well as milestone payments and royalties from partnerships that involve the co-development and commercialization of its drug candidates. Significant collaborations with larger biopharmaceutical companies also contribute to its earnings, as these partnerships often include upfront payments and potential future royalties based on sales of the jointly developed products. Additionally, MacroGenics may engage in research agreements that provide funding for the development of specific therapeutic candidates, further diversifying its revenue streams.

MacroGenics Financial Statement Overview

Summary

MacroGenics is navigating a challenging financial landscape with strengths in revenue growth and gross profit margins, but it faces significant hurdles in achieving profitability and managing cash flows. The balance sheet indicates moderate leverage, but the negative return on equity and ongoing losses suggest the need for strategic improvements to enhance financial stability and performance.

Income Statement

MacroGenics shows a mixed performance in its income statement. The company has a high gross profit margin of 89.78% TTM, indicating efficient production, but it struggles with profitability as reflected by a negative net profit margin of -36.62% TTM. Revenue growth is positive at 7.51% TTM, suggesting some growth potential, but the negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The balance sheet reveals moderate leverage with a debt-to-equity ratio of 0.47 TTM, which is manageable but has increased from previous years. The return on equity is negative at -59.84% TTM, highlighting profitability issues. The equity ratio is not explicitly provided, but the overall financial health suggests a need for improved equity management.

Cash Flow

Cash flow analysis shows a slight improvement in free cash flow growth at 3.01% TTM, but the company still faces challenges with negative operating cash flow. The free cash flow to net income ratio is positive at 1.04 TTM, indicating that the company is generating cash relative to its net losses, which is a positive sign amidst cash flow difficulties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	126.00M	148.34M	57.19M	150.02M	75.64M	97.76M
Gross Profit	92.83M	136.04M	48.97M	142.63M	72.99M	97.76M
EBITDA	-63.11M	-57.37M	2.02M	-107.89M	-190.86M	-119.10M
Net Income	-75.89M	-66.97M	-9.06M	-119.76M	-202.12M	-129.74M
Balance Sheet
Total Assets	270.76M	261.65M	298.42M	289.51M	335.25M	378.74M
Cash, Cash Equivalents and Short-Term Investments	146.40M	201.67M	229.81M	154.35M	243.62M	272.53M
Total Debt	37.01M	37.46M	33.97M	34.83M	25.47M	29.25M
Total Liabilities	203.76M	145.60M	145.81M	147.50M	95.63M	82.86M
Stockholders Equity	67.00M	116.06M	152.61M	142.01M	239.62M	295.88M
Cash Flow
Free Cash Flow	-164.76M	-72.08M	-79.97M	-90.58M	-150.03M	-117.80M
Operating Cash Flow	-162.47M	-68.37M	-78.20M	-86.96M	-143.83M	-111.90M
Investing Cash Flow	-6.64M	149.30M	-80.08M	70.72M	-36.61M	-7.79M
Financing Cash Flow	69.61M	960.00K	150.36M	1.66M	122.78M	174.34M

MacroGenics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGNX, the sentiment is Negative. The current price of 1.54 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.66, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 47.09 is Neutral, neither overbought nor oversold. The STOCH value of 50.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGNX.

MacroGenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	54 Neutral	$122.17M	-1.58	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIX	49 Neutral	$138.25M	―	-57.94%	―	―	11.78%
ORMP	47 Neutral	$93.14M	2.48	24.38%	―	―	814.20%
MGNX	45 Neutral	$94.89M	―	-81.13%	―	-9.70%	23.23%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
ATOS	36 Underperform	$109.55M	-3.77	-48.89%	―	―	-9.42%

MacroGenics Corporate Events

MacroGenics Advances in Cancer Treatment with MGC028 Clinical Trial

MacroGenics Inc. is conducting a Phase 1 clinical trial titled A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and optimal dosing of MGC028, an antibody-drug conjugate targeting ADAM9, in patients with advanced solid tumors. The primary objective is to identify potential side effects and assess the drug’s ability to control tumor progression.

MacroGenics’ Lorigerlimab Study: A Potential Game-Changer in Cancer Treatment?

Study Overview: MacroGenics Inc. is conducting a Phase 2 study titled ‘A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors.’ The study aims to assess the efficacy and safety of lorigerlimab, a bispecific DART protein, in patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer. This research is significant as it targets cancers that are resistant to conventional platinum-based treatments.

MacroGenics’ MGC026 Study: A New Hope for Advanced Cancer Treatment

MacroGenics Inc. is conducting a pivotal study titled ‘A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, and preliminary antitumor activity of MGC026, a promising treatment for various advanced cancers. This research could significantly impact treatment options for patients with challenging cancer types.

MacroGenics’ MGD024 Study: A New Hope for Blood Cancer Treatment?

MacroGenics Inc is currently conducting a Phase 1 clinical study titled ‘A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies.’ The primary objective of this study is to evaluate the safety, tolerability, and preliminary anti-cancer effects of MGD024 in patients whose blood cancers have not responded to standard therapies or have relapsed. This study is significant as it explores a novel treatment option for challenging hematologic conditions.

MacroGenics Inc. Reports Q2 2025 Financial Results

MacroGenics Inc., a clinical-stage biopharmaceutical company, specializes in developing innovative antibody-based therapeutics for cancer treatment, leveraging its proprietary antibody technology platforms. In its latest earnings report for the quarter ending June 30, 2025, MacroGenics Inc. reported total revenues of $22.2 million, a significant increase from $10.8 million in the same period last year. This growth was primarily driven by contract manufacturing revenues, which rose to $15.4 million from $2.9 million. However, the company recorded a net loss of $36.3 million, a decrease from the $55.7 million loss in the previous year, reflecting ongoing investments in research and development. Key financial highlights include a decline in cash and cash equivalents to $130.7 million from $182.8 million at the end of 2024, and a liability related to future royalties of $70.3 million following a royalty monetization arrangement. Looking ahead, MacroGenics remains focused on advancing its pipeline of product candidates and leveraging strategic collaborations to support its development efforts. The company anticipates that its current resources are sufficient to fund operations for at least the next twelve months, as it continues to explore additional financing options to support its growth strategy.

MacroGenics’ MGC026 Study: A New Hope for Advanced Solid Tumors?

MacroGenics Inc. is conducting a Phase 1/1b clinical study titled ‘A Study of MGC026 in Participants With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in patients with advanced solid tumors. This research is significant as it explores a potential new treatment option for patients with limited alternatives.